Marco Bonilla
@Nephr0s
Followers
1K
Following
4K
Media
67
Statuses
1K
Assistant Professor of Medicine @uofcneph | GN/OncoNephrology | | Northwell NS/LIJ Nephrology class ‘22| Glomerular disease fellow @GlomCon class ‘22
Chicago, IL
Joined October 2019
🚨Excited to share our new paper just out in Kidney Medicine! @jaykoyner @bdermanmd @UCCancerCenter @UChicago We report a 5-case series of CAR T-cell therapy in dialysis-dependent patients with multiple myeloma. #Onconephrology #MultipleMyeloma #CAR_T 🧵👇
1
1
7
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | New England Journal of Medicine
nejm.org
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% ...
1
8
29
Podocytopathy News: Anti-podocin ELISA guides immunotherapy in Steroid-Resistant Nephrotic Syndrome 🧐 A case illustrating how repeated testing for causative autoantibodies can guide treatment in pts with NS (and avoid CNI/CYC, ...) ▶️ https://t.co/shLRXqz6Td
1
6
30
Now open access in @NDTsocial Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD 🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors ▶️ https://t.co/5WhOOS5iUX
0
6
8
Now open access in @NDTsocial The Translational Impact of RaDaR, the UK National Registry of Rare Kidney Diseases 🧐RaDaR demonstrates how a national registry can bridge the gap between real-world data and therapeutic development ▶️ https://t.co/uBFc7PVE5V
0
8
19
1
83
241
Now online in @NDTsocial Nephrotoxicity of Non-Platinum Agents and Miscellaneous Nephrotoxic Drugs 🧐Knowing these kidney toxicity profiles is critical to maximize the oncologic benefit while preserving kidney function. ▶️ https://t.co/tO8m2hZ8hH
1
43
103
Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon's Educational Ecosystem ca. 2025 from @asnpublications @GlomCon @NWiegley @BetterCallSeeth @SaynaNorouzi @nephrologista @nikkonephro @poyanmehr
#Nephpearls Graphic by @nikkonephro 👉
2
47
164
This is excellent! If a patient with myeloma #MMsm needs CAR-T, don’t let LD fears dissuade you from getting them to the finish line. Benda is fair game, as is Flu/Cy with the schema below. I’ll be citing this in my Epic notes for sure - thanks @bdermanmd et al!
Is your center allowing for BCMA CAR T-cell therapy in patients with myeloma on dialysis for renal failure? We describe our early experience with ide-cel/cilta-cel in patients on dialysis. Bottom line: - Don't let ESKD be a barrier! - Reducing fludarabine + dialyzing each day
0
4
40
🧠Key takeaway: CAR T-cell therapy can be safely administered in dialysis-dependent patients with relapsed/refractory MM when dosing and dialysis are carefully planned.
1
0
1
How did it go? ✅ All tolerated therapy ✅ 100% achieved an initial hematologic response ⚠️ Toxicities: CRS (all grade 1–2), ICANS (1 pt), IEC-HS (3 pts) ✅One patient recovered kidney function off dialysis ☑️Some achieved MRD-negative remission beyond 1 year
1
0
0
📊What we did: We treated 5 dialysis-dependent patients (4 on hemodialysis, 1 on peritoneal dialysis) with BCMA-directed CAR T. Each received a tailored lymphodepletion regimen (dose-adjusted fludarabine/cyclophosphamide or bendamustine) and customized dialysis timing.
1
0
0
💡Why this matters: Patients with advanced CKD or on dialysis are usually excluded from CAR T trials. This leaves a major evidence gap on safety, dosing, and feasibility.
1
0
0
Is your center allowing for BCMA CAR T-cell therapy in patients with myeloma on dialysis for renal failure? We describe our early experience with ide-cel/cilta-cel in patients on dialysis. Bottom line: - Don't let ESKD be a barrier! - Reducing fludarabine + dialyzing each day
6
21
85
Chimeric Antigen Receptor T-Cell Therapy in Dialysis Dependent Patients With Multiple Myeloma: Insights From a Five-Case Series - Kidney Medicine
kidneymedicinejournal.org
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for multiple hematologic malignancies, including multiple myeloma. However, patients with advanced chronic...
0
2
7
“Glomerular Diseases and Onconephrology: A Case-Base Review” Thanks to @Nephr0s for sharing your clinical and academic expertise in this expanding field. 🫘@NefroINCMNSZ
0
17
58
Un placer haber contado con la participación de grandes ponentes internacionales en el “Módulo de Onconefrología” del @hgm_nefrologia, donde sin duda, todas sus aportaciones fueron de gran provecho para nuestros médicos residentes. @PepaSolerR, @Nephr0s, @QCasals
0
5
26
Un gusto haber contado con la ponencia de “Onconefrología y Enfermedades Glomerulares” de nuestro amigo Marco Bonilla @Nephr0s! 🦀 ¡Muy agradecidos del conocimiento y experiencia que nos compartes! 💫 @NefroINCMNSZ #OncoNeph #GlomerularDiseases
0
4
30
We are honored to welcome Dr. @kdjhaveri as our Grand Rounds speaker tomorrow! @MayoClinicNeph @HofstraKidney
2
12
78